<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04286893</url>
  </required_header>
  <id_info>
    <org_study_id>UKCLbTAVI</org_study_id>
    <nct_id>NCT04286893</nct_id>
  </id_info>
  <brief_title>Improved HRV, Inflammation Markers and Endothelial Function After TAVI</brief_title>
  <acronym>bTAVI</acronym>
  <official_title>Improved Heart Rate Variability, Inflammation Markers and Endothelial Function After Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe aortic valve stenosis is known to affect heart haemodynamics, endothelial function and
      body inflammation markers. Our aim is to investigate the weather transcatheter aortic valve
      implantation in patients with severe aortic stenosis affects heart rate variability,
      inflammation markers and endothelial function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of heart rate variability</measure>
    <time_frame>3 to 6 months after TAVI</time_frame>
    <description>Change of heart rate variability (HRV) estimated with digital high resolution ECG recording</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of laboratory value of endothelial inflammation markers</measure>
    <time_frame>3 to 6 months after TAVI</time_frame>
    <description>Laboratory determined numerical changes in endothelial inflammation markers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of flow-mediated filatation (FMD) of the brachial artery</measure>
    <time_frame>3 to 6 months after TAVI</time_frame>
    <description>% flow-mediated dilatation</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Severe Aortic Stenosis</condition>
  <condition>TAVI</condition>
  <arm_group>
    <arm_group_label>TAVI group</arm_group_label>
    <description>Consecutive patients undergoing TAVI</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Flow mediated vasodilatation</intervention_name>
    <description>Measurement of brachial artery diameter change before and after limb ischaemia.</description>
    <arm_group_label>TAVI group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>High resolution ECG</intervention_name>
    <description>Measurement HRV using high resolution ECG</description>
    <arm_group_label>TAVI group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood withdrawal</intervention_name>
    <description>Measurement of endothelial inflammation markers</description>
    <arm_group_label>TAVI group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood withdrawal for endothelial inflammation markers detection
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients eligible for transfemoral transcatheter aortic valve implantation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TAVI

        Exclusion Criteria:

          -  stage V chronic kidney disease

          -  active malignancies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Borut Jug, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Centre Ljubljana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luka Vitez</last_name>
    <phone>+38641951672</phone>
    <email>luka.vitez@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Borut Jug, PhD</last_name>
    <email>borut.jug@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMC Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Borut Jug, PhD</last_name>
      <email>borut.jug@kclj.si</email>
    </contact>
    <investigator>
      <last_name>Luka Vitez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <results_reference>
    <citation>Horn P, Stern D, Veulemans V, Heiss C, Zeus T, Merx MW, Kelm M, Westenfeld R. Improved endothelial function and decreased levels of endothelium-derived microparticles after transcatheter aortic valve implantation. EuroIntervention. 2015 Apr;10(12):1456-63. doi: 10.4244/EIJY14M10_02.</citation>
    <PMID>25287265</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Luka Vitez</investigator_full_name>
    <investigator_title>Luka Vitez, MD, cardiology resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

